216 related articles for article (PubMed ID: 22834082)
41. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting.
Mahajan HS; Mahajan MS; Nerkar PP; Agrawal A
Drug Deliv; 2014 Mar; 21(2):148-54. PubMed ID: 24128122
[TBL] [Abstract][Full Text] [Related]
42. Preparation and evaluation of fexofenadine microemulsions for intranasal delivery.
Piao HM; Balakrishnan P; Cho HJ; Kim H; Kim YS; Chung SJ; Shim CK; Kim DD
Int J Pharm; 2010 Aug; 395(1-2):309-16. PubMed ID: 20635476
[TBL] [Abstract][Full Text] [Related]
43. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins.
Khafagy el-S; Morishita M; Kamei N; Eda Y; Ikeno Y; Takayama K
Int J Pharm; 2009 Oct; 381(1):49-55. PubMed ID: 19646515
[TBL] [Abstract][Full Text] [Related]
44. Formulation and Evaluation of Niosomal in situ Nasal Gel of a Serotonin Receptor Agonist, Buspirone Hydrochloride for the Brain Delivery via Intranasal Route.
Mathure D; Madan JR; Gujar KN; Tupsamundre A; Ranpise HA; Dua K
Pharm Nanotechnol; 2018; 6(1):69-78. PubMed ID: 29380709
[TBL] [Abstract][Full Text] [Related]
45. Ursolic acid loaded intra nasal nano lipid vesicles for brain tumour: Formulation, optimization, in-vivo brain/plasma distribution study and histopathological assessment.
Khan K; Aqil M; Imam SS; Ahad A; Moolakkadath T; Sultana Y; Mujeeb M
Biomed Pharmacother; 2018 Oct; 106():1578-1585. PubMed ID: 30119233
[TBL] [Abstract][Full Text] [Related]
46. Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs.
Gonçalves VSS; Matias AA; Poejo J; Serra AT; Duarte CMM
Int J Pharm; 2016 Dec; 515(1-2):1-10. PubMed ID: 27702697
[TBL] [Abstract][Full Text] [Related]
47. Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: mechanisms of action.
Henkin RI
Nutrition; 2010 Jan; 26(1):33-9. PubMed ID: 20005465
[TBL] [Abstract][Full Text] [Related]
48. Nasal route: an alternative approach for antiemetic drug delivery.
Ozsoy Y; Güngör S
Expert Opin Drug Deliv; 2011 Nov; 8(11):1439-53. PubMed ID: 22004793
[TBL] [Abstract][Full Text] [Related]
49. Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy.
Han IK; Kim MY; Byun HM; Hwang TS; Kim JM; Hwang KW; Park TG; Jung WW; Chun T; Jeong GJ; Oh YK
J Mol Med (Berl); 2007 Jan; 85(1):75-83. PubMed ID: 17089096
[TBL] [Abstract][Full Text] [Related]
50. Preparation of bisoprolol fumarate nasal spray and its nasal delivery in rats.
Fugen G; Duo H; Gendalai M; Chunzhi W; Yi W
Pak J Pharm Sci; 2015 Nov; 28(6):2173-8. PubMed ID: 26639509
[TBL] [Abstract][Full Text] [Related]
51. [Nose-to-Brain Delivery of Peptide Drugs Enhanced by Coadministration of Cell-penetrating Peptides: Therapeutic Potential for Dementia].
Kamei N
Yakugaku Zasshi; 2017; 137(10):1247-1253. PubMed ID: 28966266
[TBL] [Abstract][Full Text] [Related]
52. Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery.
Salatin S; Barar J; Barzegar-Jalali M; Adibkia K; Milani MA; Jelvehgari M
Arch Pharm Res; 2016 Sep; 39(9):1181-92. PubMed ID: 27352214
[TBL] [Abstract][Full Text] [Related]
53. Intranasal delivery: physicochemical and therapeutic aspects.
Costantino HR; Illum L; Brandt G; Johnson PH; Quay SC
Int J Pharm; 2007 Jun; 337(1-2):1-24. PubMed ID: 17475423
[TBL] [Abstract][Full Text] [Related]
54. Advanced formulations for intranasal delivery of biologics.
Rohrer J; Lupo N; Bernkop-Schnürch A
Int J Pharm; 2018 Dec; 553(1-2):8-20. PubMed ID: 30316796
[TBL] [Abstract][Full Text] [Related]
55. Nasal route and drug delivery systems.
Türker S; Onur E; Ozer Y
Pharm World Sci; 2004 Jun; 26(3):137-42. PubMed ID: 15230360
[TBL] [Abstract][Full Text] [Related]
56. Influence of fillers in powder formulations containing N-acetyl-L-cysteine on nasal peptide absorption.
Matsuyama T; Morita T; Horikiri Y; Yamahara H; Yoshino H
J Control Release; 2007 Jul; 120(1-2):88-94. PubMed ID: 17512076
[TBL] [Abstract][Full Text] [Related]
57. A comprehensive review of advanced nasal delivery: Specially insulin and calcitonin.
Luo D; Ni X; Yang H; Feng L; Chen Z; Bai L
Eur J Pharm Sci; 2024 Jan; 192():106630. PubMed ID: 37949195
[TBL] [Abstract][Full Text] [Related]
58. Systemic delivery of peptides and proteins across absorptive mucosae.
Sayani AP; Chien YW
Crit Rev Ther Drug Carrier Syst; 1996; 13(1-2):85-184. PubMed ID: 8853960
[TBL] [Abstract][Full Text] [Related]
59. Intranasal delivery of ciprofloxacin to rats: A topical approach using a thermoreversible in situ gel.
Sousa J; Alves G; Oliveira P; Fortuna A; Falcão A
Eur J Pharm Sci; 2017 Jan; 97():30-37. PubMed ID: 27810560
[TBL] [Abstract][Full Text] [Related]
60. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives.
Ugwoke MI; Agu RU; Verbeke N; Kinget R
Adv Drug Deliv Rev; 2005 Nov; 57(11):1640-65. PubMed ID: 16182408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
